SCHEMBL13386285

SCHEMBL13386285

CN(C)c1cc(F)c2c(c1)Sc1cc(N3CCOCC3)ccc1N2C(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCHE P06276 1/20 0.39
▸ GPR119 Q8TDV5 1/20 0.39
▸ USP30 Q70CQ3 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ MAPT P10636 2/20 0.36
▸ HTT P42858 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ FAAH O00519 1/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ IDH1 O75874 1/20 0.36
▸ PIK3CA P42336 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ NPC1 O15118 2/20 0.34
▸ LGMN Q99538 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13386210 0.92 BCHE (0.42) BCHEGPR119USP30SMN1; SMN2MAPT
SCHEMBL13386133 0.89 BCHE (0.40) BCHEGPR119USP30SMN1; SMN2MAPT
SCHEMBL13386122 0.85 BCHE (0.39) BCHEGPR119USP30SMN1; SMN2RAB9A
SCHEMBL13386281 0.84 PIK3CA (0.41) BCHEGPR119USP30SMN1; SMN2MAPT
SCHEMBL12273405 0.82 BCHE (0.44) BCHEUSP30MEN1KMT2AMAPK1
SCHEMBL12272579 0.81 BCHE (0.43) BCHEMEN1KMT2AMAPK1TDP1
SCHEMBL15909028 0.80 NR1H2 (0.43) BCHEGPR119USP30SMN1; SMN2MAPT
SCHEMBL10083549 0.73 BCHE (0.61) BCHEMEN1KMT2AMAPK1TDP1
SCHEMBL2594780 0.73 PDK2 (0.46) BCHEGPR119SMN1; SMN2MAPTHTT
SCHEMBL13386253 0.72 BACE1 (0.41) BCHEGPR119USP30MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2699241-B1 ANTIVIRAL COMPOUNDS PROSETTA ANTIVIRAL INC (US) 2016-07-27 — — EP disclosed
US-8828986-B2 Antiviral compounds PROSETTA ANTIVIRAL INC. (US) 2014-09-09 — — US disclosed
EP-2699241-A1 ANTIVIRAL COMPOUNDS Prosetta Antiviral Inc. (US) 2014-02-26 — — EP disclosed
WO-2012145567-A1 ANTIVIRAL COMPOUNDS PROSETTA ANTIVIRAL INC. (US) 2012-10-26 — — WO disclosed
US-20120270854-A1 Antiviral Compounds PROSETTA ANTIVIRAL INC. (US) 2012-10-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270854-A1 Antiviral Compounds HAVCR2, MAVS, EIF2AK2 BCHE 857/4885GPR119 2643/4885USP30 1135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback